1020327-61-0

Basic information

• Product Name: phenyl pyridazin-3-ylcarbamate
• Synonyms: phenyl pyridazin-3-ylcarbamate
• CAS NO: 1020327-61-0
• Molecular Weight: 215.211
• Mol File: 1020327-61-0.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 393.3±24.0 °C(Predicted)
• Density: 1.337±0.06 g/cm3(Predicted)
• CAS DataBase Reference: phenyl pyridazin-3-ylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: phenyl pyridazin-3-ylcarbamate(1020327-61-0)
• EPA Substance Registry System: phenyl pyridazin-3-ylcarbamate(1020327-61-0)

Safety Data

• Hazardous Substances Data: 1020327-61-0(Hazardous Substances Data)

Upstream product

• 5469-70-5 3-aminopyridazine 
• 1885-14-9 phenyl chloroformate 

Downstream Products

• 1020315-31-4 PF-04457845 
• 1020317-24-1 4-(3-(5-bromopyrimidin-2-yloxy)benzylidene)-N-(pyridazin-3-yl)piperidine-1-carboxamide 
• 1020317-36-5 4-(3-(5-cyclopropylpyridin-2-yloxy)benzylidene)-N-(pyridazin-3-yl)piperidine-1-carboxamide 
• 1020317-50-3 4-(3-(6-methylpyridin-2-yloxy)benzylidene)-N-(pyridazin-3-yl)piperidine-1-carboxamide 
• 1020317-64-9 4-(3-(3-methylpyridin-2-yloxy)benzylidene)-N-(pyridazin-3-yl)piperidine-1-carboxamide 
• 1020317-78-5 4-(3-(5-methylpyridin-2-yloxy)benzylidene)-N-(pyridazin-3-yl)piperidine-1-carboxamide 
• 1020317-99-0 4-(3-(5-ethoxypyridin-2-yloxy)benzylidene)-N-(pyridazin-3-yl)piperidine-1-carboxamide 
• 1020318-13-1 4-(3-(5-(2,2,2-trifluoroethoxy)pyridin-2-yloxy)benzylidene)-N-(pyridazin-3-yl)piperidine-1-carboxamide 
• 1020318-29-9 4-(3-(5-isopropoxypyridin-2-yloxy)benzylidene)-N-(pyridazin-3-yl)piperidine-1-carboxamide 
• 1020318-67-5 4-(3-(6-(trifluoromethyl)pyridin-3-yloxy)benzylidene)-N-(pyridazin-3-yl)piperidine-1-carboxamide 
• 1020319-09-8 4-(3-bromo-5-(5-(trifluoromethyl)pyridin-2-yloxy)benzylidene)-N-(pyridazin-3-yl)piperidine-1-carboxamide 
• 1020319-16-7 4-(3-cyclopropyl-5-(5-(trifluoromethyl)pyridin-2-yloxy)benzylidene)-N-(pyridazin-3-yl)piperidine-1-carboxamide 
• 1020319-80-5 4-{3-[(4-methylpyridin-2-yl)oxy]benzylidene}-N-pyridazin-3-ylpiperidine-1-carboxamide 
• 1020320-73-3 4-(3-(5-(pyrrolidin-1-yl)pyridin-2-yloxy)benzylidene)-N-(pyridazin-3-yl)piperidine-1-carboxamide 

Relevant articles and documents

INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH)

The present invention provides compounds that are dual inhibitors of soluble epoxide hydrolase and fatty acid amide hydrolase. The present invention also provides methods of using the compounds to inhibit soluble epoxide hydrolase and fatty acid amide hydrolase, and to treat cancer.

SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS

The present invention provides substituted 4,5-dihydroisoxazole derivatives of formula (I), which may be therapeutically useful, more particularly NAMPT inhibitors and in which R1 R2, Y, X, "Het" and "p" have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPT) in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted 4,5-dihydroisoxazole derivatives of formula (I) or a pharmaceutically acceptable salts or stereoisomers or N-oxide thereof.